Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline for Cushing's Disease
NCT00889525Phase 3Completed
- Sponsor
- Seth GS Medical College and KEM Hospital
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cabergoline in Cushing's disease (CD), sponsored by Seth GS Medical College and KEM Hospital. Primary endpoint: Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl. Started Nov 2007; status: completed.
02
Drugs
cabergoline
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT00889525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00889525.